# US 2002/0160512 A1 · Ex vivo expansion of mammalian hematopoietic stem cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2002/0160512 A1
- Document ID: US20020160512A1
- Status: Published application
- Kind: A1
- Application number: 10/134,516
- Filed: 2002-04-30
- Published: 2002-10-31
- Earliest claimed: 1999-05-14
- Inventors: Chu-Chih Shih
- Web page: https://patentgrep.com/patent/US20020160512A1

## CPC

- C12N 5/0647: {Haematopoietic stem cells; Uncommitted or multipotent progenitors}
- C07K 14/4718: {Cytokine-induced proteins}
- A61K 2035/124: {the cells being hematopoietic, bone marrow derived or blood cells}
- C12N 2501/125: Stem cell factor [SCF], c-kit ligand [KL]
- C12N 2501/22: Colony stimulating factors (G-CSF, GM-CSF)
- C12N 2501/2303: Interleukin-3 (IL-3)
- C12N 2501/2306: Interleukin-6 (IL-6)
- C12N 2501/235: Leukemia inhibitory factor [LIF]
- C12N 2502/1394: Bone marrow stromal cells; whole marrow
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A method for the ex-vivo expansion of mammalian hematopoietic stem cells (HSC) comprises culturing isolated HSC in a culture system comprising a culture medium in the presence of a stem cell expansion promoting factor (SCEPF) which may be obtained by culturing murine stromal cells in the presence of an amount of leukemia inhibitory factor (LIF) sufficient to stimulate the production and secretion of said expansion promoting factor.

## Claims

### Claim 1

A method for the ex-vivo maintenance and expansion of hematopoietic stem cells (HSC) which comprises culturing HSC in a culture medium comprising a stem cell expansion promoting factor, wherein said expansion promoting factor is obtainable by a method which comprises:
culturing stromal cells in the presence of sufficient LIF to stimulate said cells to produce and secrete said expansion promoting factor.

### Claim 2 (depends on 1)

A method according to claim 1, wherein the HSC retain their ability for multilineage differentiation.

### Claim 3 (depends on 1)

A method according to claim 1, wherein the HSC retain their ability to differentiate to a myeloid lineage.

### Claim 4 (depends on 1)

A method according to claim 1, wherein the HSC retain their ability to differentiate to a B-cell lineage.

### Claim 5 (depends on 1)

A method according to claim 1, wherein the HSC retain their ability to differentiate to a T-cell lineage.

### Claim 6 (depends on 1)

A method according to claim 1, wherein the HSC are human hematopoietic stem cells.

### Claim 7 (depends on 1)

A method according to claim 1, wherein said stromal cells comprise murine stromal cells.

### Claim 8 (depends on 1)

A method according to claim 1, wherein said LIF is provided in a minimum concentration of at least about 0.5 ng/ml of medium per 1×104 stromal cells per 100 μl medium.

### Claim 9 (depends on 1)

A method according to claim 1, wherein said culture medium further comprises an additional mammalian cytokine.

### Claim 10 (depends on 6)

A method according to claim 6, wherein the cytokine comprises Il-3, Il-6, SCF, GM-CSF, FL, thrombopoietin (TPO) or a combination thereof.

### Claim 11 (depends on 10)

A method according to claim 10, wherein said culture medium further comprises Il-3 or Il-6.

### Claim 12 (depends on 10)

A method according to claim 10, wherein said culture medium further comprises TPO or SCF.

### Claim 13 (depends on 1)

A method according to claim 1, wherein said stem cell expansion promoting factor has a molecular weight in the range of about 20-30 kD.

### Claim 14

A method for the ex vivo maintenance and expansion of hematopoietic stem cells (HSC) which comprises:
(a) adding a culture medium to stromal cells and culturing said stromal cells in the presence of an amount of LIF sufficient to activate LIF receptors on said stromal cells;
(b) separating said stromal cells from said culture medium;
(c) adding isolated HSC to said medium; and
(d) culturing said HSC in said medium.

### Claim 15

A method for the ex-vivo expansion of mammalian hematopoietic stem cells (HSC) which comprises culturing isolated HSC in a culture system comprising a culture medium and stromal cells in the presence of an amount of leukemia inhibitory factor (LIF) sufficient to activate LIF receptors on said stromal cells and thereby stimulate the production and secretion of a stem cell expansion factor.

### Claim 16 (depends on 14, 15)

A method according to claim 14 or 15, wherein said stromal cells comprise murine stromal cells.

### Claim 17 (depends on 14, 15)

A method according to claim 14 or 15, wherein said medium in which said HSC are cultured further comprises an additional cytokine.

### Claim 18 (depends on 17)

A method according to claim 17, wherein said cytokine comprises Il-3, Il-6, SCF, GM-CSF, FL, thrombopoietin (TPO), or a combination thereof.

### Claim 19

A culture system suitable for the ex-vivo expansion of hematopoietic stem cells (HSC) which comprises a culture medium and stem cell expansion promoting factor.

### Claim 20 (depends on 19)

A culture system according to claim 19, which further comprises a cytokine.

### Claim 21 (depends on 20)

A culture system according to claim 20, wherein said cytokine comprises Il-3, Il-6, SCF, GM-CSF, FL, thrombopoietin (TPO) or a combination thereof.

### Claim 22 (depends on 21)

A culture system according to claim 21, which comprises Il-3 or Il-6.

### Claim 23 (depends on 21)

A culture system according to claim 21, which comprises TPO or CSF.

### Claim 24 (depends on 19)

A culture system according to claim 19, wherein said stem cell expansion promoting factor is obtainable by a method which comprises adding a culture medium to stromal cells, adding LIF to said medium, and culturing said stromal cells such that they secrete said stem cell expansion promoting factor.

### Claim 25 (depends on 23)

A culture system according to claim 23, wherein said stem cell expansion promoting factor has a molecular weight in the range of about 20-30 kD.

### Claim 26

A hematopoietic stem cell expansion factor, said factor having a molecular weight in the range of about 20-30 kD and obtainable by a method which comprises culturing stromal cells in the presence of sufficient LIF to stimulate said cells to produce and secrete said stem cell expansion factor.

### Claim 27 (depends on 26)

A hematopoietic stem cell expansion factor according to claim 26, wherein said stromal cells comprise murine stromal cells.
